Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENDRA Life Sciences Inc.NDRA · Entity 8083 | Director · Chief Executive Officer | March 02, 2026 | March 04, 2026 |
| MICROVISION, INC.MVIS · Entity 1053 | Director · President and CEO | February 08, 2017 | February 09, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENDRA Life Sciences Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 101,926 |
Reported balance
After 2026-03-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 26,921 · Balance 101,926 F1: Holdings include unvested restricted stock units ("RSUs"). F2: Represents RSUs that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 11, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Holdings include unvested restricted stock units ("RSUs").
F2: Represents RSUs that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 11, 2026.
MICROVISION, INC.
Report date February 08, 2017 · Filed February 09, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.67 · Expires 2027-02-08 | Direct | 150,000 |
Reported balance
After 2017-02-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-08 · Grant · Acquired 150,000 · Balance 150,000 F1: The reporting person vests ownership in this stock option as follows: 25% upon each annual anniversary of the date of grant, subject to the terms of the 2013 Stock Option Plan, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person vests ownership in this stock option as follows: 25% upon each annual anniversary of the date of grant, subject to the terms of the 2013 Stock Option Plan, as amended.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 4, 2026 21:48 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantCommon Stock | 26,921 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-092253 · ownership.xml · nonDerivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,926 F1 · security: Holdings include unvested restricted stock units ("RSUs"). F2 · shares: Represents RSUs that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 11, 2026. F1 · balance_after: Holdings include unvested restricted stock units ("RSUs"). Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 19:42 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-021411 · ownership.xml · nonDerivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,005 F1 · shares: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2027. Read SEC document |
| January 02, 2024 Filed Feb 23, 2024 17:00 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 600 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001209191-24-003902 · doc4.xml · derivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600 Underlying: Common Stock · 600 shares Expires 2034-01-02 F1 · shares: Represents a stock option award granted on January 2, 2024 pursuant to the Issuer's Non-Employee Director Compensation Policy. F2 · derivative.exercise_date: This stock option award becomes exercisable in three equal annual installments beginning January 2, 2025. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 20:30 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 9,621 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001209191-23-006051 · doc4.xml · derivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,621 Underlying: Common Stock · 9,621 shares Expires 2033-01-30 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024. Read SEC document |
| November 23, 2022 Filed Nov 28, 2022 17:00 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | PurchaseCommon Stock | 10,000 | $0.17 | $1,700.00 |
DisclosureSEC source: 0001209191-22-058875 · doc4.xml · nonDerivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,857 Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 08:55 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | PurchaseCommon Stock | 20,000 | $0.26 | $5,200.00 |
DisclosureSEC source: 0001209191-22-047297 · doc4.xml · nonDerivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,857 Read SEC document |
| May 16, 2022 Filed May 17, 2022 16:14 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | PurchaseCommon Stock | 100,000 | $0.20 | $19,630.00 |
DisclosureSEC source: 0001209191-22-029593 · doc4.xml · nonDerivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,857 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.1911 to $0.1963, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| March 28, 2022 Filed Mar 30, 2022 17:15 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 109,323 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001209191-22-021623 · doc4.xml · derivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,323 Underlying: Common Stock · 109,323 shares Expires 2032-03-28 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 17:07 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 12,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001209191-22-000961 · doc4.xml · derivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-01-03 F1 · shares: Represents a stock option award granted on January 3, 2022 pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 16:18 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001209191-21-025866 · doc4.xml · derivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-04-05 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022. Read SEC document |
| January 08, 2021 Filed Jan 8, 2021 19:10 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | SaleCommon Stock | 10,000 | $0.90 | $9,000.00 |
DisclosureSEC source: 0001209191-21-002827 · doc4.xml · nonDerivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,857 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan in order to pay the tax liability associated with the vesting of restricted stock units which were granted to the Reporting Person on April 9, 2020. Read SEC document |
| January 04, 2021 Filed Mar 25, 2021 17:00 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 12,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-21-023039 · doc4.xml · derivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2031-01-04 F1 · shares: Represents a stock option award granted on January 4, 2021 pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 16:46 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantCommon Stock | 42,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024217 · doc4.xml · nonDerivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,857 F1 · shares: Represents restricted stock units granted in lieu of the Reporting Person's cash retainer payable under the Issuer's Non-Employee Director Compensation Policy for the second, third and fourth quarters of 2020. The restricted stock units vest in three equal installments on the last day of each such calendar quarter. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 16:23 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 12,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001209191-20-001805 · doc4.xml · derivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-01-02 F1 · shares: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 17:53 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock option (right to buy) · Derivative | 89,585 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001209191-19-060092 · doc4.xml · derivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,585 Underlying: Common Stock · 89,585 shares Expires 2029-12-11 F1 · derivative.exercise_date: These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 20:01 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 50,000 | $0.00 Strike: $3.09 | $0.00 |
DisclosureSEC source: 0001209191-19-021506 · doc4.xml · derivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2019-03-25 F1 · shares: Represents a stock option award granted on March 25, 2019 pursuant to the Issuer's Non-Employee Director Compensation Policy. F2 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning March 25, 2020. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 19:43 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 6,061 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001654954-18-000114 · section16.xml · derivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,061 Underlying: Common Stock · 6,061 shares Expires 2026-01-02 F1 · shares: Represents a stock option award granted on January 2, 2018 pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| May 12, 2017 Filed May 18, 2017 16:25 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 12,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033586 · doc4.xml · derivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2022-05-12 Read SEC document |
| May 12, 2017 Filed May 23, 2017 18:05 UTC Amendment | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 6,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001209191-17-034737 · doc4a.xml · derivative · entry 2 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2025-05-12 F2 · derivative.exercise_date: This amendment is being filed to correct the exercisable date of these Stock Options, which was inadvertantly reported as May 12, 2017. The correct exercisable date is December 31, 2017. F1 · derivative.expiration_date: This amendment is being filed to correct the expiration date of these Stock Options, which was inadvertantly reported as May 12, 2022. The correct expiration date is May 12, 2025. Read SEC document |
| May 12, 2017 Filed May 23, 2017 18:05 UTC Amendment | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 6,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001209191-17-034737 · doc4a.xml · derivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2025-05-12 F1 · derivative.expiration_date: This amendment is being filed to correct the expiration date of these Stock Options, which was inadvertantly reported as May 12, 2022. The correct expiration date is May 12, 2025. Read SEC document |
| February 08, 2017 Filed Feb 9, 2017 22:15 UTC | MICROVISION, INC. MVIS · Entity 1053 | GrantOption (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001593968-17-000247 · primary_01.xml · derivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: MicroVision Common Stock · 150,000 shares Expires 2027-02-08 F1 · derivative.exercise_date: The reporting person vests ownership in this stock option as follows: 25% upon each annual anniversary of the date of grant, subject to the terms of the 2013 Stock Option Plan, as amended. Read SEC document |
| December 14, 2016 Filed Dec 14, 2016 21:39 UTC | MICROVISION, INC. MVIS · Entity 1053 | PurchaseCommon Stock | 46,730 | $1.07 | $50,001.10 |
DisclosureSEC source: 0001593968-16-001319 · primary_01.xml · nonDerivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,721 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.